ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Deerfield launches first international venture with $130 million

by Megha Satyanarayana
January 10, 2020 | APPEARED IN VOLUME 98, ISSUE 2

 

09802-buscon16-weizmann.jpg
Credit: The Weizmann Institute
The Weizmann Institute

The life sciences investment firm Deerfield Management has signed its first international agreement, pledging up to $130 million over 10 years to a collaboration with Yeda Research and Development, the commercial arm of Israel’s Weizmann Institute of Science. The new company, Orchard Innovations, will develop medicines based on Weizmann research. This is Deerfield’s second recent academic partnership in as many months. In December, the firm entered a similar $130 million pact with Duke University.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment